Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Jun;21(6):1013–1015. doi: 10.1128/aac.21.6.1013

Evaluation of Urinary Elimination of N-Acetyl-β-Glucosaminidase in Healthy Volunteers Treated with Dibekacin or Gentamicin

J Camí 1, J Segura 1, J E Baños 1, I Garcia 1, L Drobnic 1
PMCID: PMC182065  PMID: 7114833

Abstract

The urinary excretion of N-acetyl-β-glucosaminidase was studied in healthy subjects during and after treatment with aminoglycosides. In terms of this parameter dibekacin appeared to be less nephrotoxic than gentamicin.

Full text

PDF
1013

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borooah J., Leaback D. H., Walker P. G. Studies on glucosaminidase. 2. Substrates for N-acetyl-beta-glucosaminidase. Biochem J. 1961 Jan;78(1):106–110. doi: 10.1042/bj0780106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dieppe P. A., Doyle D. V., Burry H. C. Renal damage during treatment with antirheumatic drugs. Br Med J. 1978 Sep 2;2(6138):664–664. doi: 10.1136/bmj.2.6138.664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hamada M., Homma Y., Tamamura T., Kondo S. Antibacterial activity of dibekacin against gentamicin-resistant organisms. Jpn J Antibiot. 1977 Feb;30(2):203–205. [PubMed] [Google Scholar]
  4. Hultberg B., Nordén N., Ockerman P. A. Urinary excretion of acid hydrolases in disease. Scand J Clin Lab Invest. 1972 Oct;30(2):215–219. doi: 10.3109/00365517209081113. [DOI] [PubMed] [Google Scholar]
  5. Lockwood T. D., Bosmann H. B. The use of urinary N-acetyl-beta-glucosaminidase in human renal toxicology. I. Partial biochemical characterization and excretion in humans and release from the isolated perfused rat kidney. Toxicol Appl Pharmacol. 1979 Jun 30;49(2):323–336. doi: 10.1016/0041-008x(79)90257-6. [DOI] [PubMed] [Google Scholar]
  6. Lockwood T. D., Bosmann H. B. The use of urinary N-acetyl-beta-glucosaminidase in human renal toxicology. II. Elevation in human excretion after aspirin and sodium salicylate. Toxicol Appl Pharmacol. 1979 Jun 30;49(2):337–345. doi: 10.1016/0041-008x(79)90258-8. [DOI] [PubMed] [Google Scholar]
  7. Rankin L. I., Luft F. C., Yum M. N., Isaacs L. L. Comparative nephrotoxicities of dibekacin, amikacin, and gentamicin in a rat model. Antimicrob Agents Chemother. 1980 Dec;18(6):983–985. doi: 10.1128/aac.18.6.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Wellwood J. M., Ellis B. G., Price R. G., Hammond K., Thompson A. E., Jones N. F. Urinary N-acetyl- beta-D-glucosaminidase activities in patients with renal disease. Br Med J. 1975 Aug 16;3(5980):408–411. doi: 10.1136/bmj.3.5980.408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Whelton A., Carter G. G., Stout R. L., Herbst D. V., Bryant H. H., Walker G. Dibekacin intrarenal distribution characteristics and renal cortical elution kinetics. Comparison with gentamicin and tobramycin. J Clin Pharmacol. 1980 Aug-Sep;20(8-9):518–525. doi: 10.1002/j.1552-4604.1980.tb02545.x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES